Cited by 3,114T-cell and B-cell ImmunologyCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.

Molecular mechanisms of T cell co-stimulation and co-inhibition

Open access

Chen, Lieping, Flies, Dallas B.·2013·Nature Reviews Immunology

Open this paper in CoChat — free account

Abstract

Co-stimulatory and co-inhibitory receptors have a pivotal role in T cell biology, as they determine the functional outcome of T cell receptor (TCR) signalling. The classic definition of T cell co-stimulation continues to evolve through the identification of new co-stimulatory and co-inhibitory receptors, the biochemical characterization of their downstream signalling events and the delineation of their immunological functions. Notably, it has been recently appreciated that co-stimulatory and co-inhibitory receptors display great diversity in expression, structure and function, and that their functions are largely context dependent. Here, we focus on some of these emerging concepts and review the mechanisms through which T cell activation, differentiation and function is controlled by co-stimulatory and co-inhibitory receptors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nri3405

Cites

135 of 135 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
T cell exhaustion
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
The B7 family revisited
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,072
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860

Flagged first, then by citations

Show all 135 references

Research works printed but not linked: 1

Lafferty, K. J. & Cunningham, A. J. A. New analysis of allogeneic interactions. J. Immunol. 112, 436–437 (1975). Lafferty and Cunningham extended the Bretscher and Cohn two-signal model to suggest that T cells require two signals for activation.

Sorted by citations

Items 701–800 of 1,003

New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone
Hu‐Lieskovan, S., & Ribas, A. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000246 · Cited by 52
B7-DC (PD-L2) costimulation of CD4+ T-helper 1 response via RGMb
Nie, X., Chen, W., Zhu, Y., Huang, B., Yu, W., Wu, Z., Guo, S., Zhu, Y., Luo, L., Wang, S., et al. (2017) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.17 · Cited by 52
Self-citation
Clinical Development of PD-1 in Advanced Melanoma
Munhoz, R. R., & Postow, M. A. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000299 · Cited by 50
Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: A pre-clinical study in a murine model
Zhu, J., Yu, M., Chen, L., Kong, P., Li, L., Ma, G., Ge, H., Cui, Y., Li, Z., Pan, H., et al. (2018) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2017.12.011 · Cited by 52
Self-citation
Extracellular Purine Metabolism Is the Switchboard of Immunosuppressive Macrophages and a Novel Target to Treat Diseases With Macrophage Imbalances
Ohradanova‐Repic, A., Machacek, C., Charvet, C., Lager, F., Roux, D. L., Platzer, R., Leksa, V., Mitulović, G., Burkard, T. R., Zlabinger, G. J., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00852 · Cited by 53
Helper T‐cell responses and pulmonary fungal infections
McDermott, A. J., & Klein, B. S. (2018) · Immunology · doi:10.1111/imm.12953 · Cited by 51
Treatment Combining CD200 Immune Checkpoint Inhibitor and Tumor-Lysate Vaccination after Surgery for Pet Dogs with High-Grade Glioma
Olin, M. R., Ampudia-Mesias, E., Pennell, C. A., Sarver, A. L., Chen, C. C., Moertel, C. L., Hunt, M. A., & Pluhar, G. E. (2019) · Cancers · doi:10.3390/cancers11020137 · Cited by 52
BAFF promotes T cell activation through the BAFF-BAFF-R-PI3K-Akt signaling pathway
Hu, S., Wang, R., Zhang, M., Liu, K., Tao, J., Tai, Y., Zhou, W., Wang, Q., & Wei, W. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108796 · Cited by 52
PD-1/PD-L1 axis importance and tumor microenvironment immune cells
Lotfinejad, P., Kazemi, T., Mokhtarzadeh, A., Shanehbandi, D., Jadidi‐Niaragh, F., Safaei, S., Asadi, M., & Baradaran, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118297 · Cited by 52
Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study
Wang, Q., Ye, Y., Yu, H., Lin, S., Tu, H., Liang, D., Chang, D. W., Huang, M., & Wu, X. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02718-1 · Cited by 53
The costimulatory activity of Tim-3 requires Akt and MAPK signaling and its recruitment to the immune synapse
Kataoka, S., Manandhar, P., Lee, J., Workman, C. J., Banerjee, H., Szymczak-Workman, A. L., Kvorjak, M., Lohmueller, J. J., & Kane, L. (2021) · Science Signaling · doi:10.1126/scisignal.aba0717 · Cited by 52
PD-1, CTLA-4, LAG-3, and TIGIT: The roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions
Esen, F., Deniz, G., & Çetin, E. A. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.09.009 · Cited by 52
Intracellular hydrogelation preserves fluid and functional cell membrane interfaces for biological interactions
Lin, J., Chien, C.-Y., Lin, C.-L., Yao, B., Chen, Y., Liu, Y.-H., Fang, Z.-S., Chen, J.-Y., Chen, W.-Y., Lee, N.-N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09049-5 · Cited by 52
Current concepts of non-coding RNA regulation of immune checkpoints in cancer
Smolle, M. A., Prinz, F., Calin, G. A., & Pichler, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.09.007 · Cited by 51
Polysialic Acid in the Immune System
Villanueva-Cabello, T. M., Gutiérrez-Valenzuela, L. D., Salinas-Marín, R., López-Guerrero, D. V., & Martínez-Duncker, I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.823637 · Cited by 50
Immunosuppressive biomaterial-based therapeutic vaccine to treat multiple sclerosis via re-establishing immune tolerance
Nguyen, T. L., Choi, Y., Im, J., Shin, H., Phan, N. M., Kim, M. K., Choi, S. W., & Kim, J. (2022) · Nature Communications · doi:10.1038/s41467-022-35263-9 · Cited by 60
Adoptive Cell Therapy for Nonhematologic Solid Tumors
Olson, D. J., & Odunsi, K. O. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01618 · Cited by 53
Ginsenoside compound K suppresses the abnormal activation of T lymphocytes in mice with collagen-induced arthritis
Liu, K.-K., Wang, Q., Yang, S.-M., Chen, J., Wu, H.-X., & Wei, W. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.7 · Cited by 51
Paramyxovirus Activation and Inhibition of Innate Immune Responses
Parks, G. D., & Alexander‐Miller, M. A. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.09.015 · Cited by 51
CD4+ T Cells Promote the Pathogenesis of Staphylococcus aureus Pneumonia
Parker, D., Ryan, C., Alonzo, F., Torres, V. J., Planet, P. J., & Prince, A. S. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu525 · Cited by 51
Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis.
Javan, M. R., Aslani, S., Zamani, M. R., Rostamnejad, J., Asadi, M., Farhoodi, M., & Nicknam, M. H. (2016) · PubMed · Cited by 50
Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis—a pilot study
Jovanović, D. M., Milenković, M. R., Stevuljević, J. K., Marković, J., Krstić, V. Ć., Kontić, M., & Škodrić-Trifunović, V. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.11.16 · Cited by 51
Unraveling the Mechanobiology of the Immune System
Kim, J., Shin, Y. J., Ha, L. J., Kim, D., & Kim, D. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801332 · Cited by 52
B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes
Linsley, P. S., Greenbaum, C. J., Speake, C., Long, S. A., & Dufort, M. J. (2019) · JCI Insight · doi:10.1172/jci.insight.126136 · Cited by 51
Cooperation between T cell receptor and Toll-like receptor 5 signaling for CD4 + T cell activation
Rodríguez-Jorge, O., Kempis-Calanis, L. A., Abou-Jaoudé, W., Gutiérrez‐Reyna, D. Y., Hernandez, C., Ramírez-Pliego, O., Thomas‐Chollier, M., Spicuglia, S., Santana, M. A., & Thieffry, D. (2019) · Science Signaling · doi:10.1126/scisignal.aar3641 · Cited by 46
Network Approaches for Dissecting the Immune System
Shi, H., Yan, K., Ding, L., Qian, C., Chi, H., & Yu, J. (2020) · iScience · doi:10.1016/j.isci.2020.101354 · Cited by 51
Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy
Buqué, A., Bloy, N., Aranda, F., Cremer, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., Tartour, É., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1149674 · Cited by 50
CD84 cell surface signaling molecule: An emerging biomarker and target for cancer and autoimmune disorders
Cuenca, M., Sintes, J., Lányi, Á., & Engel, P. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.10.017 · Cited by 53
Structure–Activity Relationship Study of Amidobenzimidazole Analogues Leading to Potent and Systemically Administrable Stimulator of Interferon Gene (STING) Agonists
Song, Z., Wang, X., Zhang, Y., Gu, W., Shen, A., Ding, C., Han, L., Xiao, R., Geng, M., Xie, Z., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01900 · Cited by 54
1α,25(OH) 2 D 3 reverses exhaustion and enhances antitumor immunity of human cytotoxic T cells
Li, P., Zhu, X., Cao, G., Wu, R., Li, K., Yuan, W., Chen, B., Sun, G., Xia, X., Zhang, H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003477 · Cited by 51
“51 A previous study has shown that the TCR, Ca 2+ , and CD28 together form a dual- positive-feedback circuit that substantially amplifies T-cell signaling and thus increases antigen sensitivity.”
Update in TIGIT Immune-Checkpoint Role in Cancer
Annese, T., Tamma, R., & Ribatti, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871085 · Cited by 54
“T cells immunoediting also occurs during tumorigenesis (26, 27).”
Background
IFI16 phase separation via multi-phosphorylation drives innate immune signaling
Liu, D., Lum, K. K., Treen, N., Núñez, C. T., Yang, J., Howard, T. R., Levine, M., & Cristea, I. M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad449 · Cited by 49
Treg cell: Critical role of regulatory T-cells in depression
Gao, X. W., Tang, Y., Kong, L., Fan, Y., Wang, C., & Wang, R. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106893 · Cited by 51
Immunotherapy-related biomarkers: Confirmations and uncertainties
Catalano, M., Iannone, L. F., Nesi, G., Nobili, S., Mini, E., & Roviello, G. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104135 · Cited by 61
CD19 CAR Therapy for Acute Lymphoblastic Leukemia
Sadelain, M., Brentjens, R. J., Rivière, I., & Park, J. H. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e360 · Cited by 50
Novel Immune Check-Point Regulators in Tolerance Maintenance
Guo, Y., & Wang, A. Y. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00421 · Cited by 50
Exhaustion of the CD8+ T Cell Compartment in Patients with Mutations in Phosphoinositide 3-Kinase Delta
Wentink, M., Mueller, Y. M., Dalm, V., Driessen, G., van Hagen, P. V., van Montfrans, J. V., van der Burg, M., & Katsikis, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00446 · Cited by 48
CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection
Khairnar, V., Duhan, V., Patil, A., Zhou, F., Bhat, H., Thöns, C., Sharma, P., Adomati, T., Friendrich, S.-K., Bezgovsek, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04832-2 · Cited by 49
A Mechanistic Computational Model Reveals That Plasticity of CD4+ T Cell Differentiation Is a Function of Cytokine Composition and Dosage
Puniya, B. L., Todd, R. G., Mohammed, A., Brown, D. M., Barberis, M., & Helikar, T. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00878 · Cited by 50
Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma
Locke, F. L., Go, W. Y., & Neelapu, S. S. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3869 · Cited by 51
Immunometabolic responses according to physical fitness status and lifelong exercise during aging: New roads for exercise immunology
Padilha, C. S., Figueiredo, C., Minuzzi, L. G., Chimin, P., Deminice, R., Krüger, K., Neto, J. C. R., & Lira, F. S. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101341 · Cited by 54
Immuno-regulatory antibodies for the treatment of cancer
Honeychurch, J., Cheadle, E. J., Dovedi, S. J., & Illidge, T. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1036737 · Cited by 49
Vaccine approaches for antigen capture by liposomes
Zhou, S., Luo, Y., & Lovell, J. F. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2274479 · Cited by 52
“Co-stimulation for B cells or T cells achieved through the CD40-CD40L pathway, and the CD80/86-CD28 pathway are important for effective immune responses [15–17].”
Background
Pregnancy promotes tolerance to future offspring by programming selective dysfunction in long-lived maternal T cells
Barton, B. M., Xu, R., Wherry, E. J., & Porrett, P. M. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.1a0316-135r · Cited by 50
Reduced risk of apoptosis: mechanisms of stress responses
Milisav, I., Poljšak, B., & Ribarič, S. (2016) · APOPTOSIS · doi:10.1007/s10495-016-1317-3 · Cited by 49
PLGA nanoparticles loaded with beta-lactoglobulin-derived peptides modulate mucosal immunity and may facilitate cow's milk allergy prevention
Kostadinova, A. I., Middelburg, J., Ciulla, M., Garssen, J., Hennink, W. E., Knippels, L. M. J., van Nostrum, C. F., & Willemsen, L. E. M. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.051 · Cited by 49
PD-1 has a unique capacity to inhibit allergen-specific human CD4+ T cell responses
Rosskopf, S., Jahn‐Schmid, B., Schmetterer, K. G., Zlabinger, G. J., & Steinberger, P. (2018) · Scientific Reports · doi:10.1038/s41598-018-31757-z · Cited by 50
PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
Wang, Y., & Li, G. (2019) · Frontiers of Medicine · doi:10.1007/s11684-018-0674-4 · Cited by 49
Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy
Belcaid, Z., Berrevoets, C., Choi, J. H., van Beelen, E. S. A., Stavrakaki, Ε., Pierson, T., Kloezeman, J. J., Routkevitch, D., van der Kaaij, M., van der Ploeg, A., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa011 · Cited by 49
Molecular mechanisms and therapeutic implications of tetrandrine and cepharanthine in T cell acute lymphoblastic leukemia and autoimmune diseases
Xu, W., Chen, S., Wang, X., Tanaka, S., Onda, K., Sugiyama, K., Yamada, H., & Hirano, T. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107659 · Cited by 49
High MHC-II expression in Epstein–Barr virus-associated gastric cancers suggests that tumor cells serve an important role in antigen presentation
Ghasemi, F., Tessier, T. M., Gameiro, S. F., Maciver, A. H., Cecchini, M. J., & Mymryk, J. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-71775-4 · Cited by 50
Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma
Lin, E., Liu, X., Liu, Y., Zhang, Z., Xie, L., Tian, K., Liu, J., & Yu, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.653358 · Cited by 51
A myriad of roles of dendritic cells in atherosclerosis
Zhao, Y., Zhang, J., Zhang, W., & Xu, Y. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13634 · Cited by 49
Innate Immune Cells and Hypertension: Neutrophils and Neutrophil Extracellular Traps (NETs)
McCarthy, C. G., Saha, P., Golonka, R. M., Wenceslau, C. F., Joe, B., & Vijay–Kumar, M. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200020 · Cited by 48
Concise Review: Skeletal Muscle as a Delivery Route for Mesenchymal Stromal Cells
Jahromi, S. H., & Davies, J. E. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0208 · Cited by 48
Structural Basis of VSIG3: The Ligand for VISTA
Xie, X., Chen, C., Chen, W., Jiang, J., Wang, L., Li, T., Sun, H., & Liu, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.625808 · Cited by 48
Resistance to immune checkpoint inhibitors and the tumor microenvironment
Kawashima, S., & Togashi, Y. (2022) · Experimental Dermatology · doi:10.1111/exd.14716 · Cited by 50
The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
Moeckel, C. M., Bakhl, K., Georgakopoulos‐Soares, I., & Zaravinos, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076710 · Cited by 52
“Since then, ICIs, which block a selected inhibitory pathway’s effects in order to overcome immunosuppressive conditions, have become the standard of care when treating many malignancies (Figure 2E) [63,65,70].”
Background
Immunomodulation and immunopharmacology in heart failure
Markousis‐Mavrogenis, G., Baumhove, L., Al‐Mubarak, A. A., Aboumsallem, J. P., Bömer, N., Voors, A. A., & van der Meer, P. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00919-6 · Cited by 51
“A second co-stimulatory signal from specific surface receptors (such as CD40, CD70, CD80 and CD86) on APCs is required to prevent inappropriate T cell activation 23 .”
Cancer vaccines as enablers of immunotherapy
Khleif, S. N., & Gupta, S. (2025) · Nature Immunology · doi:10.1038/s41590-025-02308-2 · Cited by 56
“These molecules can further enhance priming and T cell activation and differentiation 13 .”
Cutting Edge: DNAX Accessory Molecule 1–Deficient CD8+ T Cells Display Immunological Synapse Defects That Impair Antitumor Immunity
Ramsbottom, K. M., Hawkins, E. D., Shimoni, R., McGrath, M., Chan, C. J., Russell, S. M., Smyth, M. J., & Oliaro, J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1302197 · Cited by 48
Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway
Wang, R., Xu, A., Zhang, X., Wu, J., Freywald, A., Xu, J., & Xiang, J. (2016) · Cellular and Molecular Immunology · doi:10.1038/cmi.2016.23 · Cited by 48
Immunologic challenges of human reproduction: an evolving story
Hyde, K. J., & Schust, D. J. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.07.1073 · Cited by 50
T cell immunotherapy enhanced by designer biomaterials
Dunn, Z. S., Mac, J., & Wang, P. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119265 · Cited by 48
Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy
Hensen, L. C. M., Hoeben, R. C., & Bots, S. T. F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186828 · Cited by 48
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
You, G., Won, J., Lee, Y., Moon, D., Park, Y., Lee, S. H., & Lee, S. (2021) · Vaccines · doi:10.3390/vaccines9070724 · Cited by 52
Engineering strategies for broad application of TCR-T- and CAR-T-cell therapies
Watanabe, K., & Nishikawa, H. (2021) · International Immunology · doi:10.1093/intimm/dxab052 · Cited by 50
CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients
Lü, N., Liu, J., Xu, M., Liang, J., Wang, Y., Wu, Z., Xing, Y. T., & Diao, F. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s335592 · Cited by 48
The NOD Mouse Beyond Autoimmune Diabetes
Aubin, A., Lombard‐Vadnais, F., Collin, R., Aliesky, H. A., McLachlan, S. M., & Lesage, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.874769 · Cited by 51
Lymph node macrophages drive innate immune responses to enhance the anti-tumor efficacy of mRNA vaccines
Kubara, K., Yamazaki, K., Miyazaki, T., Kondo, K., Kurotaki, D., Tamura, T., & Suzuki, Y. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.020 · Cited by 51
CD4+ T-cell survival in the GI tract requires dectin-1 during fungal infection
Drummond, R. A., Dambuza, I. M., Vautier, S., Taylor, J. A., Reid, D. M., Bain, C. C., Underhill, D. M., Masopust, D., Kaplan, D. H., & Brown, G. D. (2015) · Mucosal Immunology · doi:10.1038/mi.2015.79 · Cited by 49
Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia
Knaus, H. A., Kanakry, C. G., Luznik, L., & Gojo, I. (2017) · Current Drug Targets · doi:10.2174/1389450116666150518095346 · Cited by 47
Constrained Cyclic Peptides as Immunomodulatory Inhibitors of the CD2:CD58 Protein–Protein Interaction
Sable, R. V., Durek, T., Taneja, V., Craik, D. J., Pallerla, S., Gauthier, T. J., & Jois, S. D. S. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00486 · Cited by 47
TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy
Liu, X., Hou, M., & Liu, Y. (2016) · Immunological Investigations · doi:10.1080/08820139.2016.1237524 · Cited by 47
Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS
Sugio, T., Miyawaki, K., Kato, K., Sasaki, K., Yamada, K., Iqbal, J., Miyamoto, T., Ohshima, K., Maeda, T., Miyoshi, H., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018018754 · Cited by 47
From biomarkers to therapeutic targets: the promise of PD-L1 in thyroid autoimmunity and cancer
D’Andréa, G., Lassalle, S., Guevara, N., Mograbi, B., & Hofman, P. M. (2020) · Theranostics · doi:10.7150/thno.50333 · Cited by 47
Hierarchy of signaling thresholds downstream of the T cell receptor and the Tec kinase ITK
Gallagher, M. P., Conley, J. M., Vangala, P., Garber, M. G., Reboldi, A., & Berg, L. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025825118 · Cited by 51
Correction: HTLV-1 bZIP Factor Enhances T-cell Proliferation by Impeding the Suppressive Signaling of Co-inhibitory Receptors
Kinosada, H., Yasunaga, J., Shimura, K., Miyazato, P., Onishi, C., Iyoda, T., Inaba, K., & Matsuoka, M. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006228 · Cited by 46
Insulin Signaling in Arthritis
Tripolino, C., Ciaffi, J., Pucino, V., Ruscitti, P., van Leeuwen, N., Borghi, C., Giacomelli, R., Meliconi, R., & Ursini, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672519 · Cited by 46
Novel Treatments in Lupus
Vukelic, M., Li, Y., & Kyttaris, V. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02658 · Cited by 47
Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy
Cai, H., Li, M., Deng, R., Wang, M., & Shi, Y. (2022) · Biomarker Research · doi:10.1186/s40364-022-00413-0 · Cited by 46
“Other inhibitors or agonists of immune checkpoint molecules, including the inhibitors of CTLA4, LAG3, Tim3, and TIGIT, as well as the agonists of OX40, are currently in clinical trials in the treatment of gastric cancer.”
BackgroundInfluential
Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression
Asano, Y., Kashiwagi, S., Goto, W., Takada, K., Takahashi, K., Morisaki, T., Fujita, H., Takashima, T., Tomita, S., Ohsawa, M., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1458-y · Cited by 46
The dynamic interactions between the stroma, pancreatic stellate cells and pancreatic tumor development: Novel therapeutic targets
Farran, B., & Nagaraju, G. P. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.07.001 · Cited by 45
Downregulation of inhibitory SRC homology 2 domain-containing phosphatase-1 (SHP-1) leads to recovery of T cell responses in elderly
Le Page, A., Fortin, C., Garneau, H., Allard, N., Tsvetkova, K., Tan, C. T. Y., Larbi, A., Dupuis, G., & Fülöp, T. (2014) · Cell Communication and Signaling · doi:10.1186/1478-811x-12-2 · Cited by 44
Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity
Yadollahi, P., Jeon, Y., Ng, W. L., & Choi, I. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.241 · Cited by 46
Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer
Kang, Y., & Cai, Y. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i32.5362 · Cited by 46
Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions
Haddad, A. F., Young, J. S., Gill, S. A., & Aghi, M. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.019 · Cited by 47
Boolean logic in synthetic biology and biomaterials: Towards living materials in mammalian cell therapeutics
Bressler, E. M., Adams, S. C., Liu, R., Colson, Y. L., Wong, W. W., & Grinstaff, M. W. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1244 · Cited by 45
Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy
Lu, S., Wang, C., Ma, J., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1456030 · Cited by 49
“T-cell activation requires two signals: an initial signal triggered by the antigen from the T cell receptor (TCR) and a subsequent signal from co-stimulatory receptors (146).”
Background
Enteric glial cells have specific immunosuppressive properties
Kermarrec, L., Durand, T., Neunlist, M., Naveilhan, P., & Neveu, I. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.04.011 · Cited by 45
Checkpoint Inhibitors and Their Application in Breast Cancer
Bedognetti, D., Maccalli, C., Bader, S. B. J. A., Marincola, F. M., & Seliger, B. (2016) · Breast Care · doi:10.1159/000445335 · Cited by 49
Antigen Presentation After Stroke
Miró‐Mur, F., Urra, X., Gallizioli, M., Chamorro, Á., & Planas, A. M. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0469-8 · Cited by 47
Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1
McNiel, E. A., & Tsichlis, P. N. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.45 · Cited by 45
Extracellular Vesicles Transfer the Receptor Programmed Death-1 in Rheumatoid Arthritis
Greisen, S. R., Yan, Y., Hansen, A. S., Venø, M. T., Nyengaard, J. R., Moestrup, S. K., Hvid, M., Freeman, G. J., Kjems, J., & Deleuran, B. W. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00851 · Cited by 45
Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways
Bewersdorf, J. P., Shallis, R. M., & Zeidan, A. M. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100709 · Cited by 44
T-cell-based breast cancer immunotherapy
Pilipow, K., Darwich, A., & Losurdo, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.019 · Cited by 44
Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review
Haibe, Y., Husseini, Z. E., Sayed, R. E., & Shamseddine, A. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176176 · Cited by 45
Synergistic ferroptosis and macrophage re-polarization using engineering exosome-mimic M1 nanovesicles for cancer metastasis suppression
Li, P., Gao, M., Hu, Z., Xu, T., Chen, J., Ma, Y., Li, S., & Gu, Y. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.128217 · Cited by 45
Recurrent Sepsis Exacerbates CD4+ T Cell Exhaustion and Decreases Antiviral Immune Responses
He, W., Xiao, K., Xu, J., Guan, W. P., Xie, S., Wang, K., Yan, P., Fang, M., & Xie, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627435 · Cited by 45
Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations
Tabana, Y., Moon, T. C., Siraki, A. G., Elahi, S., & Barakat, K. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1937123 · Cited by 47

Authors: Chen, L., & Flies, D. B.
Affiliations: Yale Cancer Center (US)
University of New Mexico (US)
Corresponding author: Chen, Lieping
ORCID: Chen, Lieping
Flies, Dallas B.
Venue: Nature Reviews Immunology
Publisher: Springer Science and Business Media LLC
Published: 2013-03-08
Volume: 13
Issue: 4
Pages: 227-242
ISSN: 1474-1733 (ISSN-L)
1474-1741
DOI: 10.1038/nri3405
PMC: PMC3786574
OpenAlex: W2130473166
Cited by: 3,114
References: 135
Citations by year: 2026: 148 · 2025: 258 · 2024: 259 · 2023: 276 · 2022: 305 · 2021: 312 · 2020: 310 · 2019: 250 · 2018: 275 · 2017: 238 · 2016: 195 · 2015: 148 · 2014: 101 · 2013: 35
FWCI: 13.52
Type: journal article
Language: en
Update notices: erratum (2013-06-05)
Open access: green
europepmc.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature reviews. Immunology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Melanoma Research Alliance
National Cancer Institute (CA 97085, CA 16359, CA121974, CA86721, R01CA097085, CA142779, R01CA085721, R01CA142779, P50CA121974, P30CA016359)
National Institute of Allergy and Infectious Diseases (T32AI089704, R01AI072592, AI72592, T32AI007247)
Topics: Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: T cell costimulation, T cell co-inhibition, costimulatory receptors, co-inhibitory receptors, T cell receptor signaling, T cell activation, T cell differentiation, immune checkpoint molecules
MeSH terms: Humans, Lymphocyte Activation, Receptors, Antigen, T-Cell, T-Lymphocytes, Signal Transduction, CD28 Antigens, B7-1 Antigen, Models, Immunological, B7-2 Antigen, Receptors, Tumor Necrosis Factor, Member 14

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Molecular mechanisms of T cell co-stimulation and co-inhibition

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks